NAS:COCH (USA)
Â
Ordinary Shares - Class A
$
0.72
-0.0013 (-0.18%)
09:42 AM EST
Business Description
Envoy Medical Inc
NAICS : 423450
SIC : 3845
ISIN : US29415V1098
Share Class Description:
COCH: Ordinary Shares - Class ATotal Employee Number:
47Description
Envoy Medical Inc is a hearing health company focused on providing medical technologies across the hearing loss spectrum. Its product portfolio comprises: the Esteem FI-AMEI, a fully implanted active middle ear implant (FI -AMEI) that works with the ear's natural anatomy, and is FDA-approved for adults with moderate to severe sensorineural hearing loss; and Acclaim CI, an investigational cochlear implant under development. The company derives all of its revenue substantially from the sale of the Esteem FI-AMEI implants and their replacement components. It has one reportable segment: hearing.
Financial Strength
3/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Cash-To-Debt | 28.4 | |||||
Equity-to-Asset | 0.35 | |||||
Debt-to-Equity | 0.08 | |||||
Debt-to-EBITDA | -0.04 | |||||
Piotroski F-Score | 4/9 | |||||
Altman Z-Score | -15.04 | |||||
WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Revenue Growth Rate | -24.2 | |||||
3-Year EBITDA Growth Rate | -3.4 | |||||
3-Year EPS without NRI Growth Rate | 7.6 | |||||
3-Year FCF Growth Rate | 3.9 | |||||
3-Year Book Growth Rate | 39.6 | |||||
Future 3-5Y Total Revenue Growth Rate Estimate | 388.66 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
5-Day RSI | 46.5 | |||||
9-Day RSI | 52.43 | |||||
14-Day RSI | 53.42 | |||||
3-1 Month Momentum % | -0.6 | |||||
6-1 Month Momentum % | -4.63 | |||||
12-1 Month Momentum % | -54.86 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Current Ratio | 2.27 | |||||
Quick Ratio | 2.14 | |||||
Cash Ratio | 2.07 | |||||
Days Inventory | 601.55 | |||||
Days Sales Outstanding | 57.71 | |||||
Days Payable | 803.84 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -14 | |||||
Shareholder Yield % | -50.11 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
Gross Margin % | -310.68 | |||||
Operating Margin % | -9881.2 | |||||
Net Margin % | -9875.64 | |||||
EBITDA Margin % | -9273.5 | |||||
FCF Margin % | -8850.43 | |||||
OCF Margin % | -8776.5 | |||||
ROA % | -172.85 | |||||
ROIC % | -763.91 | |||||
3-Year ROIIC % | -925.24 | |||||
ROC (Joel Greenblatt) % | -1122.36 | |||||
ROCE % | -595.29 | |||||
Moat Score | 5 | |||||
Tariff Resilience Score | 5 |
GF Value Rank
4/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
PS Ratio | 72.47 | |||||
PB Ratio | 5.18 | |||||
Price-to-Tangible-Book | 5.18 | |||||
EV-to-EBIT | -1.43 | |||||
EV-to-Forward-EBIT | -1.43 | |||||
EV-to-EBITDA | -1.45 | |||||
EV-to-Revenue | 134.42 | |||||
EV-to-Forward-Revenue | 131.48 | |||||
EV-to-FCF | -1.52 | |||||
Price-to-GF-Value | 0.64 | |||||
| Price-to-Net-Current-Asset-Value | 6.59 | |||||
| Price-to-Net-Cash | 9.06 | |||||
Earnings Yield (Greenblatt) % | -69.93 | |||||
FCF Yield % | -37.1 |
Operating Revenue by Business Segment
Operating Revenue by Geographic Region
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:COCH
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Envoy Medical Inc Executives
DetailsAnalyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | 0.234 | ||
| EPS (TTM) ($) | -1.01 | ||
| Beta | - | ||
| 3-Year Sharpe Ratio | - | ||
| 3-Year Sortino Ratio | - | ||
| Volatility % | 50.35 | ||
| 14-Day RSI | 53.42 | ||
| 14-Day ATR ($) | 0.071555 | ||
| 20-Day SMA ($) | 0.68609 | ||
| 12-1 Month Momentum % | -54.86 | ||
| 52-Week Range ($) | 0.3625 - 1.89 | ||
| Shares Outstanding (Mil) | 77.02 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 4 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Envoy Medical Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Envoy Medical Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| Third quarter earnings results for 2026 | 2026-11-10 | In 124 days | ||
| Second quarter earnings results for 2026 | 2026-07-31 | In 22 days | ||
| Life Sciences Virtual Investor Forum | 2026-06-25 13:00 | 0.63 (-5.50%) | ||
| General meeting for 2026 | 2026-05-12 15:00 | 0.64 (-6.67%) | ||
| First quarter earnings results for 2026 | 2026-05-11 | 0.65 (-4.93%) | ||
| Fourth quarter earnings results for 2025 | 2026-03-23 08:30 | 0.78 (-6.04%) | ||
| Annual report for 2025 | 2026-03-23 | 0.78 (-6.04%) | ||
| Small Cap Growth Virtual Investor Conference | 2026-02-05 10:00 | 0.58 (-2.01%) | ||
| Third quarter earnings results for 2025 | 2025-11-10 | 0.70 (+0.06%) | ||
| Second quarter earnings results for 2025 | 2025-07-31 | 1.56 (-0.51%) |
Show
Entries
Envoy Medical Inc Frequently Asked Questions
What is Envoy Medical Inc(COCH)'s stock price today?
The current price of COCH is $0.72. The 52 week high of COCH is $1.89 and 52 week low is $0.36.
When is next earnings date of Envoy Medical Inc(COCH)?
The next earnings date of Envoy Medical Inc(COCH) is 2026-07-31 Est..
Does Envoy Medical Inc(COCH) pay dividends? If so, how much?
Envoy Medical Inc(COCH) does not pay dividend.
Guru Commentaries on NAS:COCH
No articles.
Press Release
Articles on Envoy Medical Inc
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers